TOMI Reports Strong Q1 2026 Sales of High-Margin BIT Solution, Indicating Positive Growth Trends
Rhea-AI Summary
TOMI (NASDAQ: TOMZ) reported preliminary unaudited BIT Solution sales of approximately $427,000 in Q1 2026, following annual BIT growth from $872,380 in 2024 to $1,065,172 in 2025. Q1 orders totaled about $3,360,000 with ~$1.7M recognized revenue. TOMI expects to sell 10 55-gallon drums in 2026 and says current orders position the company to potentially exceed $12 million in fiscal 2026 revenue.
The update emphasizes TOMI's razor-and-blade model where high-margin BIT consumables (historical gross margins >80%) drive recurring revenue tied to SteraMist system adoption.
Positive
- BIT revenue increased ~22% from 2024 to 2025
- Q1 BIT sales of approximately $427,000
- Q1 orders $3.36M supporting FY2026 upside
- BIT gross margins historically exceeding 80%
Negative
- Key figures are preliminary and unaudited
- 55-gallon drum sales historically concentrated in H2
- FY2026 $12M revenue outcome described as potential, not guaranteed
News Market Reaction – TOMZ
On the day this news was published, TOMZ gained 1.77%, reflecting a mild positive market reaction. This price movement added approximately $203K to the company's valuation, bringing the market cap to $11.70M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | Q1 2026 update | Positive | -2.3% | Preliminary Q1 2026 revenue and order strength highlighted across offerings. |
| Apr 06 | Adoption update | Positive | -10.5% | Reported rising SteraMist adoption among compounding pharmacies amid tighter standards. |
| Mar 31 | Full-year 2025 results | Neutral | +5.4% | Detailed 2025 revenue decline, margins, losses, financing actions, and growth pipeline. |
| Mar 26 | Earnings call notice | Neutral | +0.0% | Announced timing and access details for Q4 2025 results conference call. |
| Mar 25 | Regulatory approval | Positive | -5.0% | BIT Solution gained Dutch ctgb PT2 authorization under EU BPR for SteraMist use. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive operating or regulatory updates have often been met with negative or muted price reactions, indicating a pattern of divergence between fundamentals-focused news and share performance.
Recent releases showed improving activity but inconsistent price responses. On Mar 31, TOMI reported $5.64M 2025 revenue and a $3.75M net loss, with shares rising 5.37%. However, a Netherlands BIT authorization on Mar 24 and a Q1 2026 revenue update of about $1.7M plus $3.36M in sales and open orders both coincided with declines of ‑4.95% and ‑2.26%. Adoption gains in compounding pharmacies on Apr 6 also saw a ‑10.46% move, underscoring repeated divergence.
Key Terms
razor and blade business model financial
epa-registered regulatory
steramist technical
automated integration builds technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREDERICK, Md., April 14, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection/decontamination solutions, reports preliminary unaudited BIT Solution revenue for the first quarter of 2026. TOMI employs a Razor and Blade business model for iHP decontamination. The Company sells a durable primary delivery system (the “razor”) under the SteraMist brand, at a competitive price point. Delivery system sales drive ongoing demand for our EPA-registered BIT solution, a high-margin consumable (the “blade”). BIT Solution sales have historically generated gross margins in excess of
Since 2024, BIT solution sales have shown steady annual growth, increasing from
TOMI sells 55-gallon drums, which play a crucial role in SteraMist automated integration builds and contribute to ongoing high-margin recurring revenue. Historically, sales of these 55-gallon drums occur in the latter half of the year; in 2024, TOMI sold five (5) 55-gallon drums, increasing to seven (7) drums in 2025. This year, TOMI anticipates selling ten (10) drums, driven by a growing pipeline of automated integration builds scheduled for delivery by year-end.
As noted in the Company’s previous press release, total orders produced in the first quarter amounted to approximately
Dr. Halden Shane, CEO of TOMI Environmental Solutions commented, “Our razor-razor blade model is beginning to show tangible results after years of growing the installed base of SteraMist delivery systems with customers. The primary goal of the Company is to achieve sustained and growing profitability. The timeline for achieving this has always been largely dependent on how quickly the iHP technology can foster customer adoption, establishing a recurring revenue stream from our proprietary BIT Solution sales, a high-margin consumable which offsets the initial hardware sales.”
About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.
For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to preliminary financial results, including preliminary revenue information, estimated open orders, BIT Solution sales, and estimated total integration pipeline, expected revenue growth in 2026 and beyond, TOMI’s products and services to serve the life sciences sector, and the ability to complete delivery of products and services pursuant to purchase orders. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These may include, but are not limited to, our ability to acquire new customers and expands sales; our projected revenue and revenue recognized from anticipated future purchase orders, invoiced orders, and contracts, our ability to maintain and manage growth and generate sales (equipment and consumable), our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Zach Nevas
IMS Investor Relations
tomi@imsinvestorrelations.com
